Novartis posts daNIS-3 phase 2 results; registers Phase 3 PINNACLE-MI cardiac trialNov 16Weekly roundup, 4 itemsNovartis
Novartis updates pediatric asciminib CML trial; opens new schizophrenia drug studyNov 13Weekly roundup, 6 itemsasciminibinotuzumab ozogamicin
The company: FDA grants accelerated approval to asciminib for newly diagnosed chronic myeloid leukemNov 10Regulatory decisionasciminibNovartisRecord notice
Novartis ends open-label extension study of pelacarsen after Lp(a)HORIZON missNov 10Trial updateNovartispelacarsen
FDA approved ribociclib combinations for early high-risk breast cancer in 2024Nov 10Regulatory decisionNovartisribociclib
FDA approves dabrafenib plus trametinib for BRAF V600E low-grade glioma in childrenNov 10Regulatory decisiondabrafenibNovartis
Novartis Capital Corporation prices $5.5 billion four-tranche notes offeringNov 10FinancingNovartisUpdated
Novartis terminates phase III KontRASt-02 trial of JDQ443 in lung cancerNov 6Trial updateNovartisopnurasib
FDA approves Lutathera for pediatric GEP-NET patients 12 and olderNov 6Regulatory decisionlutetium lu 177 dotatateNovartis
Novartis registers two Phase I trials: TRB191 in SCLC and XEP527 in schizophreniaNov 6Weekly roundup, 10 itemsArdtartemether and lumefantrine
Allarity settles $4.9 million Novartis liability, signs first CLIA lab services dealNov 2PartnershipAllarity TherapeuticsNovartis
Novartis posts Cosentyx nail psoriasis and imatinib results; Piqray label updatedOct 30Weekly roundup, 8 itemsalpelisibeverolimusUpdated
Amgen's MariTide cardiovascular outcomes trial surfaces; OASIS pediatric migraine results holdOct 29Weekly roundup, 2 itemsAmgenmaridebart cafraglutideUpdated
Novartis updates Phase IIIb ribociclib adjuvant breast cancer trial; four prior items holdOct 23Weekly roundup, 5 itemsarumakimigNovartisUpdated
Novartis clinicaltrials.gov records update across scleroderma, urticaria and SMA studiesOct 16Weekly roundup, 7 itemsianalumabNovartis
Genentech's mycophenolate pregnancy registry listed as completed, last updated October 2026Oct 16Weekly roundup, 4 itemsAmneal Pharmaceuticals, LLCastegolimabUpdated
Novartis terminates Phase 2 iptacopan lupus nephritis trial after Part 1Oct 15Trial updateiptacopanNovartis
Novartis withdraws planned phase 2 retreatment study of ianalumab in ITP and wAIHAOct 15Trial updateianalumabNovartis
FDA approves supplement 13 for Cosentyx, Novartis's secukinumabOct 15Regulatory decisionNovartissecukinumab
Novartis registers new Phase 2 NIO752 tauopathy trial; Egaten results, six studies updateOct 9Weekly roundup, 8 itemsinclisiraniptacopanUpdated